Reid Ian R
Department of Medicine, University of Auckland, New Zealand.
Curr Opin Rheumatol. 2003 Jul;15(4):458-63. doi: 10.1097/00002281-200307000-00014.
In the course of 2002, several new studies were published confirming the efficacy of bisphosphonate drugs in fracture prevention in patients with osteoporosis. Further evidence was provided of their long duration of action, making intermittent administration possible. The potent bisphosphonate zoledronate can be given at intervals of as long as 1 year and produces changes in bone density and in markers of bone turnover comparable with those seen with conventional daily oral dosing with alendronate or risedronate. If such regimens are proven to prevent fractures, their convenience is likely to result in their widespread adoption and potentially an increase in compliance with these medications. Further evidence has been presented documenting the value of bisphosphonates in preventing the skeletal complications of malignancy, and possibly in reducing mortality in patients with breast cancer. The role of bisphosphonates in osteogenesis imperfecta was further confirmed, and novel roles in ankylosing spondylitis, myelofibrosis, and hypertrophic pulmonary osteoarthropathy were suggested.
在2002年期间，发表了几项新的研究，证实了双膦酸盐药物在预防骨质疏松症患者骨折方面的疗效。进一步的证据表明了它们作用持续时间长，使得间歇性给药成为可能。强效双膦酸盐唑来膦酸盐可以间隔长达1年给药，并且产生的骨密度变化和骨转换标志物变化与阿仑膦酸盐或利塞膦酸盐常规每日口服给药时所见的变化相当。如果此类给药方案被证明可预防骨折，其便利性可能会导致它们被广泛采用，并可能提高对这些药物的依从性。已提出进一步的证据证明双膦酸盐在预防恶性肿瘤的骨骼并发症方面的价值，并且可能在降低乳腺癌患者的死亡率方面有价值。双膦酸盐在成骨不全中的作用得到进一步证实，并提示其在强直性脊柱炎、骨髓纤维化和肥厚性肺骨关节病中的新作用。
